Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all

Podobne knjige/članki

• Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study
  od: Marshall, Alison D., et al.
  Izdano: (2016)
• Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
  od: Al-Busafi, Said A., et al.
  Izdano: (2017)
• Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era
  od: Falade-Nwulia, Oluwaseun, et al.
  Izdano: (2018)
• Roadblocks to Accessing Direct-Acting Antiviral Agents for Treatment of Hepatitis C Virus Infection
  od: Bernstein, David E.
  Izdano: (2015)
• Disparities in direct acting antivirals uptake in HIV‐hepatitis C co‐infected populations in Canada
  od: Saeed, Sahar, et al.
  Izdano: (2017)